RNF216 Variants Found in Patients With Dementia, Hypogonadotropic Hypogonadism, and Severe Ataxia Deregulate Autophagy

RNF216 loss-of-function variants kill cells via runaway autophagy — found in 2 of 1,476 HH patients

Journal: The Journal of Clinical Endocrinology and Metabolism | Published: 2026-04-22 | Type: Journal Article | PMID: 41271602 Authors: Young J, Abdennebi I, Le Saëc M, et al. (Université Paris-Saclay / Inserm, Le Kremlin-Bicêtre) Funding/COI: Institut National de la Santé et de la Recherche Médicale, Paris-Saclay University, Société Française d'Endocrinologie. No COI declared.

Summary

RNF216 is an E3 ubiquitin ligase that normally puts a brake on Beclin-1, a master regulator of autophagy. When the gene is broken, that brake fails, autophagy goes into overdrive, and cells die — apparently in both the hypothalamic-pituitary axis (causing hypogonadotropic hypogonadism) and the cerebellum (causing ataxia and dementia). This paper screened 1,476 patients with hypogonadotropic hypogonadism (HH), found one family carrying a homozygous nonsense variant (p.Arg686*), and then confirmed in cell culture that this and other previously reported RNF216 variants all disrupt autophagy the same way. The mechanism is autophagic cell death, not apoptosis: blocking autophagy with 3-MA rescued cells, while the pan-caspase inhibitor Z-VAD did nothing.

Claims

• 1 family (2 affected patients) with the homozygous RNF216 variant c.2056C>T (p.Arg686*) identified among 1,476 HH patients — a prevalence of roughly 0.14% in this cohort
• Patients presented with HH plus late-onset ataxia and dementia
• Cells expressing the variant showed disrupted autophagy regulation consistent with loss-of-function
• RNF216 knockdown reduced cell viability; death was not blocked by Z-VAD (pan-caspase inhibitor) but was blocked by 3-MA (autophagy inhibitor)
• Multiple previously published RNF216 variants associated with this syndrome showed the same functional profile in vitro

Study Quality

This is a mechanistic case study, not an epidemiological or clinical trial. The cohort screen (1,476 patients) is large for a rare monogenic syndrome and establishes prevalence context, but the clinical phenotype rests on just 2 patients from 1 family — a sample so small it can describe the syndrome but cannot generalize it. The in vitro work is the real contribution: the authors demonstrate a coherent mechanism using multiple variant types and two different pharmacological probes (Z-VAD and 3-MA), which strengthens the causal argument beyond what a single variant-knockout experiment would. The use of exome analysis rather than targeted panel sequencing is appropriate for rare variant discovery.

The study is entirely cell-based for mechanism; no animal model is used, so the leap from "cells die by autophagy in a dish" to "this explains cerebellar degeneration in humans" is a reasonable hypothesis, not a demonstrated fact.

Red Flags

• Clinical phenotype rests on 2 patients from a single family — cannot distinguish disease mechanism from family-specific modifier effects
• In vitro cell model may not recapitulate tissue-specific autophagy dynamics in neurons or GnRH-secreting cells
• No patient-derived cells or iPSCs; all functional work is in transfected cell lines
• Funding from the French Endocrinology Society is low-risk for bias, but no explicit COI disclosure beyond "not listed"
• 3-MA is a non-selective autophagy inhibitor with off-target effects; rescue by 3-MA alone is suggestive, not definitive

Strengths

• Large HH cohort (n=1,476) gives a meaningful denominator for prevalence estimation
• Mechanism is internally consistent: disrupted Beclin-1 regulation → autophagy → cell death, with pharmacological rescue data
• Multiple independent RNF216 variants tested, all showing the same functional signature — reduces the chance this is a variant-specific artifact
• Clean negative control: Z-VAD ruling out classical apoptosis is important

Verdict

A tight mechanistic paper that finally puts a molecular explanation behind a syndrome that has been clinically described for years without a clear "why." The science is credible for what it claims — an in vitro demonstration of autophagy dysregulation — and appropriately restrained about what it doesn't prove. The clinical data is thin by necessity: this is a genuinely rare syndrome, and 2 patients from 1 family is what it is. Worth reading for anyone in rare endocrine genetics or autophagy biology; of limited direct clinical utility until someone builds a larger patient registry.